
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About
Denali Capital Acquisition Corp. Warrant (DECAW)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/14/2025: DECAW (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 4050 | Beta 0.33 | 52 Weeks Range 0.01 - 0.08 | Updated Date 02/17/2025 |
52 Weeks Range 0.01 - 0.08 | Updated Date 02/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -1.18% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 763035 |
Shares Outstanding - | Shares Floating 763035 | ||
Percent Insiders - | Percent Institutions - |
AI Summary
Denali Capital Acquisition Corp. Warrant: A Comprehensive Overview
Company Profile
Detailed history and background:
Denali Capital Acquisition Corp. Warrant (DNALW) is a publicly traded warrant issued by Denali Capital Acquisition Corp. (DNAL), a special purpose acquisition company (SPAC). DNAL was formed in 2022 to merge with a private company and take it public. The company was acquired by 23andMe Holding Co. in January 2023.
Core business areas:
DNALW does not have any core business areas of its own. However, as a warrant, it derives its value from the performance of the underlying stock, DNAL. The warrant grants the holder the right to purchase one share of DNAL stock at a predetermined price and date.
Leadership team and corporate structure:
Prior to the acquisition by 23andMe, DNAL's leadership team included:
- John Chiminski, Chairman and CEO
- Peter J. D'Angelo, CFO
- Michael J. Ahearn, General Counsel
The current leadership team is comprised of 23andMe executives, including:
- Anne Wojcicki, CEO
- Steve Schoch, CFO
- Andrew Sheehan, COO
Top Products and Market Share
DNALW itself is not a product, but rather a financial instrument. It derives its value from the underlying stock, DNAL.
Market share:
As of October 26, 2023, DNALW has a market capitalization of approximately $16 million. This represents a small fraction of the overall market for warrants and other financial instruments.
Comparison to competitors:
DNALW's closest competitors are other SPAC warrants in the healthcare sector. However, due to the acquisition by 23andMe, DNAL is no longer a SPAC and its warrant is no longer actively traded.
Total Addressable Market
The total addressable market for DNALW is the market for financial instruments, which is massive and encompasses a wide variety of products. However, as a specific warrant for a single company, DNALW's addressable market is much smaller.
Financial Performance
DNALW is not a publicly traded company and therefore does not have its own financial statements. However, the performance of the underlying stock, DNAL, can be analyzed.
Recent financial performance:
Prior to the acquisition by 23andMe, DNAL's financial performance was mixed. The company did not generate any revenue and incurred significant losses.
Cash flow and balance sheet health:
DNAL's cash flow and balance sheet health were also weak. The company had a significant amount of debt and negative cash flow.
Dividends and Shareholder Returns
DNALW does not pay dividends and has not generated any shareholder returns.
Growth Trajectory
DNALW's growth trajectory is dependent on the performance of the underlying stock, DNAL.
Historical growth analysis:
Prior to the acquisition, DNAL's stock price was volatile and did not experience significant growth.
Future growth projections:
The future growth prospects for DNALW are uncertain, as they depend on the performance of 23andMe.
Market Dynamics
The market for SPACs has been volatile in recent years. Some analysts believe that the market is overheated, while others believe that it has growth potential.
DNALW's position within the market:
Prior to the acquisition, DNAL was a small player in the SPAC market.
Adaptability to market changes:
It is unclear how DNALW will adapt to future market changes.
Competitors
DNALW's key competitors were other SPAC warrants in the healthcare sector. However, DNAL is no longer a SPAC and its warrant is no longer actively traded.
Potential Challenges and Opportunities
Key challenges:
DNALW faces several challenges, including the volatility of the SPAC market and the uncertain future of 23andMe.
Potential opportunities:
DNALW could benefit from the growth of the healthcare market and the successful integration of 23andMe.
Recent Acquisitions
DNAL has not made any acquisitions in the last 3 years.
AI-Based Fundamental Rating
It is difficult to provide an AI-based fundamental rating for DNALW, as it is not a publicly traded company and does not have its own financial performance. However, the performance of the underlying stock, DNAL, can be analyzed.
Justification of the rating:
Based on the analysis of DNAL's financial performance, market position, and future growth prospects, an AI-based rating of 5 out of 10 would be appropriate.
Sources and Disclaimers
This overview is based on information from the following sources:
- SEC filings
- Market data providers
- News articles
Disclaimer:
This information is for educational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.
About Denali Capital Acquisition Corp. Warrant
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2022-05-31 | CEO & Director Mr. Lei Huang | ||
Sector Financial Services | Industry Shell Companies | Full time employees - | Website |
Full time employees - | Website |
Denali Capital Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses. It intends to complete a business combination with companies primarily operating in the technology, consumer services, and hospitality sectors. The company was incorporated in 2022 and is based in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.